What are the key drivers behind Gilead's revenue growth in 2024?

Gilead's revenue growth in 2024 was primarily driven by the following key factors: 1. **HIV Product Sales**: Biktarvy, Gilead's HIV treatment, experienced a significant increase in sales, growing by 10% year-over-year to $2.9 billion. This product's strong performance was a major contributor to the company's revenue growth. 2. **Oncology Sales**: Oncology sales increased by 18% year-over-year to $789 million. The growth in oncology sales, particularly from products like Biktarvy, was a notable driver of revenue growth. 3. **Liver Disease Sales**: Gilead's liver disease therapies, including Veklury and Epclusa, contributed to the revenue growth with a 6% increase in sales excluding Veklury. The company's focus on treating chronic hepatitis B and C has been successful, with products like Biktarvy and Veklury playing significant roles in this segment. 4. **New Product Introductions**: The acquisition of CymaBay Therapeutics brought Gilead another potentially transformative therapy for people with liver disease, which could contribute to future revenue growth. In summary, Gilead's revenue growth in 2024 was driven by strong sales of its HIV, Oncology, and Liver Disease products, with key contributors including Biktarvy and Veklury.